SymBio Pharmaceuticals Limited (TYO:4582)
Japan
· Delayed Price · Currency is JPY 118.00
+3.00 (2.61%)
Mar 10, 2026, 11:30 AM JST
SymBio Pharmaceuticals Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 2,884 | 3,963 | 6,517 | 6,282 | 3,860 | Upgrade
|
| Cash & Short-Term Investments | 2,884 | 3,963 | 6,517 | 6,282 | 3,860 | Upgrade
|
| Cash Growth | -27.24% | -39.19% | 3.74% | 62.74% | 0.30% | Upgrade
|
| Accounts Receivable | 259.68 | 423 | 913 | 2,084 | 2,148 | Upgrade
|
| Receivables | 259.68 | 423 | 913 | 2,084 | 2,148 | Upgrade
|
| Inventory | 288.95 | 238 | 232 | 469 | 385.68 | Upgrade
|
| Prepaid Expenses | 60.28 | 110 | 119 | 209 | 145.01 | Upgrade
|
| Other Current Assets | 331.65 | 190 | 301 | 268 | 209.53 | Upgrade
|
| Total Current Assets | 3,824 | 4,924 | 8,082 | 9,312 | 6,748 | Upgrade
|
| Property, Plant & Equipment | - | - | - | 69 | 83.64 | Upgrade
|
| Long-Term Investments | 0.02 | 44 | 87 | 85 | - | Upgrade
|
| Other Intangible Assets | - | - | - | 222 | 259.1 | Upgrade
|
| Long-Term Deferred Tax Assets | 5.9 | - | - | 744 | 1,276 | Upgrade
|
| Other Long-Term Assets | 37.35 | - | 1 | 1 | 86.66 | Upgrade
|
| Total Assets | 3,867 | 4,968 | 8,170 | 10,433 | 8,453 | Upgrade
|
| Accounts Payable | 468.27 | - | - | 46 | 69.68 | Upgrade
|
| Accrued Expenses | - | - | - | - | 516.04 | Upgrade
|
| Current Portion of Long-Term Debt | 682.5 | - | - | - | - | Upgrade
|
| Current Income Taxes Payable | 118.55 | 737 | 872 | 1,564 | 383.6 | Upgrade
|
| Other Current Liabilities | 21.05 | 29 | 84 | 313 | 548.79 | Upgrade
|
| Total Current Liabilities | 1,290 | 766 | 956 | 1,923 | 1,518 | Upgrade
|
| Long-Term Debt | 1,300 | - | - | - | - | Upgrade
|
| Pension & Post-Retirement Benefits | 4.91 | 4 | 3 | 3 | 2.78 | Upgrade
|
| Other Long-Term Liabilities | - | 3 | 1 | 2 | 186.44 | Upgrade
|
| Total Liabilities | 2,595 | 773 | 960 | 1,928 | 1,707 | Upgrade
|
| Common Stock | 19,244 | 18,336 | 17,952 | 17,548 | 17,158 | Upgrade
|
| Additional Paid-In Capital | 19,219 | 18,311 | 17,927 | 17,523 | 17,133 | Upgrade
|
| Retained Earnings | -37,462 | -32,685 | -28,852 | -26,889 | -27,978 | Upgrade
|
| Treasury Stock | -89.87 | -89 | -89 | -88 | -86.05 | Upgrade
|
| Comprehensive Income & Other | 360.8 | 322 | 272 | 411 | 519.1 | Upgrade
|
| Shareholders' Equity | 1,272 | 4,195 | 7,210 | 8,505 | 6,746 | Upgrade
|
| Total Liabilities & Equity | 3,867 | 4,968 | 8,170 | 10,433 | 8,453 | Upgrade
|
| Total Debt | 1,983 | - | - | - | - | Upgrade
|
| Net Cash (Debt) | 901 | 3,963 | 6,517 | 6,282 | 3,860 | Upgrade
|
| Net Cash Growth | -77.27% | -39.19% | 3.74% | 62.74% | 0.30% | Upgrade
|
| Net Cash Per Share | 17.94 | 87.88 | 163.32 | 158.62 | 99.38 | Upgrade
|
| Filing Date Shares Outstanding | 59.48 | 47.83 | 44.75 | 39.52 | 38.37 | Upgrade
|
| Total Common Shares Outstanding | 59.48 | 45.84 | 42.19 | 39.52 | 38.37 | Upgrade
|
| Working Capital | 2,534 | 4,158 | 7,126 | 7,389 | 5,230 | Upgrade
|
| Book Value Per Share | 21.39 | 91.52 | 170.89 | 215.22 | 175.78 | Upgrade
|
| Tangible Book Value | 1,272 | 4,195 | 7,210 | 8,283 | 6,487 | Upgrade
|
| Tangible Book Value Per Share | 21.39 | 91.52 | 170.89 | 209.60 | 169.03 | Upgrade
|
| Buildings | 172.77 | - | - | - | 64.62 | Upgrade
|
| Machinery | 81.35 | - | - | - | 72.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.